F Kong1, Y Qi2, H Liu3, F Gao4, P Yang3, Y Li5, Y Jia6. 1. Department of Oncology, First Teaching Hospital of Tianjin University of TCM, Anshanxi Road, Nankai District, Tianjin, 300193, China. kongfanming08@163.com. 2. Department of Hematology, Tianjin First Center Hospital, Fukang Road, Tianjin, 300192, China. 3. Department of Oncology, First Teaching Hospital of Tianjin University of TCM, Anshanxi Road, Nankai District, Tianjin, 300193, China. 4. Department of Pediatrics, Tianjin Medical University General Hospital, Anshan Road, Tianjin, 300052, China. 5. Department of Hematology, Tianjin First Center Hospital, Fukang Road, Tianjin, 300192, China. dr_liyuming@sina.com. 6. Department of Oncology, First Teaching Hospital of Tianjin University of TCM, Anshanxi Road, Nankai District, Tianjin, 300193, China. jiayingjie1616@163.com.
Abstract
BACKGROUNDS: Recurrence is the most important factor associated with death of gastric cancer patients after surgery. The aim of this study was to explore the prognosis factors and the effective therapy for recurrent gastric cancer (RGC) patients after radical resection. METHODS: The clinical data of 144 RGC patients who underwent radical resection from January 1999 to March 2004 were reviewed. The 15 clinicopathological factors and treatment modalities on the survival were analyzed. Univariate and multivariate analyses were performed to investigate the prognostic significance of these factors for RGC. RESULTS: The early recurrence (<2 years) was found in 90 patients, while late recurrence (≥2 years) occurred in 54 patients. The 2-year cumulative survival rates were 23.8 % for recurrent patients receiving chemotherapy plus surgery vs. 1.2 % in patients having chemotherapy only (p < 0.001), while the median survival time was 11.0 months vs. 6.0 months (p < 0.001). Multivariate analysis indicated TNM stage after the first operation (p = 0.048), iASPP overexpression (p = 0.013), time to recurrence (p < 0.001) and treatment of recurrence (p < 0.001) as independent prognostic factors. CONCLUSIONS: Surgery combined with chemotherapy for recurrent gastric cancer patients achieves ideal long-term prognosis, which should perform actively.
BACKGROUNDS: Recurrence is the most important factor associated with death of gastric cancerpatients after surgery. The aim of this study was to explore the prognosis factors and the effective therapy for recurrent gastric cancer (RGC) patients after radical resection. METHODS: The clinical data of 144 RGC patients who underwent radical resection from January 1999 to March 2004 were reviewed. The 15 clinicopathological factors and treatment modalities on the survival were analyzed. Univariate and multivariate analyses were performed to investigate the prognostic significance of these factors for RGC. RESULTS: The early recurrence (<2 years) was found in 90 patients, while late recurrence (≥2 years) occurred in 54 patients. The 2-year cumulative survival rates were 23.8 % for recurrent patients receiving chemotherapy plus surgery vs. 1.2 % in patients having chemotherapy only (p < 0.001), while the median survival time was 11.0 months vs. 6.0 months (p < 0.001). Multivariate analysis indicated TNM stage after the first operation (p = 0.048), iASPP overexpression (p = 0.013), time to recurrence (p < 0.001) and treatment of recurrence (p < 0.001) as independent prognostic factors. CONCLUSIONS: Surgery combined with chemotherapy for recurrent gastric cancerpatients achieves ideal long-term prognosis, which should perform actively.
Authors: Di Zhang; Song Li; Wenbin Yu; Cheng Chen; Teng Liu; Yiting Sun; Zeyi Zhao; Lian Liu Journal: Cancer Manag Res Date: 2018-10-09 Impact factor: 3.989